FDA criticized for restricting the use of COVID antibody treatments

(Natural News) The Food and Drug Administration (FDA) was criticized for revising the emergency use authorization for the Wuhan coronavirus antibody treatments from Regeneron and Eli Lilly. The drugs, bamlanivimab and etesevimab (which are administered together) and REGEN-COV (casirivimab and imdevimab) were limited in their use, allegedly because they are unlikely to work against the omicron variant....